Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL952090 | 0.88 | TSHR (0.38) | TSHRSOAT1ALDH1A1 | |
| SCHEMBL4154813 | 0.80 | — | — | |
| SCHEMBL3148591 | 0.80 | — | — | |
| SCHEMBL11475673 | 0.78 | — | — | |
| SCHEMBL950259 | 0.76 | ALDH1A1 (0.33) | TSHRALDH1A1 | |
| SCHEMBL952092 | 0.76 | NAAA (0.37) | TSHRSOAT1ALDH1A1 | |
| SCHEMBL953463 | 0.76 | TSHR (0.31) | TSHR | |
| SCHEMBL249383 | 0.75 | TSHR (0.38) | TSHRSOAT1ALDH1A1 | |
| SCHEMBL1083281 | 0.75 | LMNA (0.39) | SOAT1 | |
| SCHEMBL5424391 | 0.75 | TSHR (0.38) | TSHRSOAT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
| EP-1960391-A1 | PIPERAZINE DERIVATIVES AND THEIR USE IN THERAPY | Vernalis (R&D) Limited (GB) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007057687-A1 | PIPERAZINE DERIVATIVES AND THEIR USE IN THERAPY | VERNALIS (R & D) LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | TSHR 506/4885SOAT1 1366/4885ALDH1A1 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.